Please note: This work was supported by U54 TR001433-05, National Center for Advancing Translational Sciences, National Institutes of Health. Dr. Fayad has received consulting fees from Alexion and GlaxoSmithKline; has received research funding from Daiichi-Sankyo, Amgen, Bristol-Myers Squibb, and Siemens Healthineers; and has received financial compensation as a board member and advisor to and owns equity as a co-founder of Trained Therapeutix Discovery. Dr. Nadkarni has received financial compensation as a consultant and Advisory Board member for and owns equity in RenalytixAI; is a scientific co-founder of RenalytixAI and Pensieve Health; has received operational funding from Goldfinch Bio; and has received consulting fees from BioVie Inc., AstraZeneca, Reata, and GLG consulting in the past 3 years. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. PK Shah, MD, served as Guest Editor-in-Chief and Guest Associate Editor for this paper.